Sjögren's syndrome is a systemic autoimmune disease characterized by sicca symptoms and B lymphocyte hyperactivity. Hematological abnormalities are common in Sjögren's syndrome, including anemia, leukopenia, thrombocytopenia, and lymphoproliferative disorders. These hematologic involvements are mostly recognized as mild laboratory abnormalities. Life-threatening, severe thrombocytopenia is very rare. We describe a patient with primary Sjögren's syndrome, who developed very severe thrombocytopenia during the clinical course and successfully treated with high dose dexamethasone therapy.
Introduction
Sjögren's syndrome is a chronic autoimmune disease with broad spectrum manifestations, the most prevalent being decreased lacrimal and salivary gland function. It can occur alone (primary Sjögren's syndrome) or in association with other rheumatic diseases (secondary Sjögren's syndrome).
Patients with primary Sjögren's syndrome have a wide range of hematologic abnormalities, including hemocytopenia, hypergammaglobulinemia, and monoclonal gammopathy (1) .
Hemocytopenia is detected in 1/3 of patients, may develop as isolated cytopenia or pancytopenia (2, 3) . Although these alterations are usually mild without need for treatment, some patients may present severe symptomatic cytopenia (3) (4) (5) .
Thrombocytopenia in Sjögren's syndrome seems to be caused by platelet destruction due to either antiplatelet antibody or immune complex formation (6) . Clinically significant severe thrombocytopenia is very rare, only a few cases have been reported in the literature (5,7-9). We report a rare case of patient with primary Sjögren's syndrome who developed very severe thrombocytopenia.
Case Report
A 50-year-old woman was admitted to the hospital for evaluation of purpura and mucosal bleeding. She had been given a diagnosis of primary Sjögren's syndrome 6 years ago and treated with pilocarpine and tear substitutes. Over this follow-up period, no other rheumatic disease has developed. Two weeks ago, she noticed epistaxis, gum bleeding, and multiple ecchymoses and purpura on her body. Mechanisms of action of corticosteroids on immune thrombocytopenia may be explained as follows: has a direct lymphocytic effect, accelerates lymphocyte apoptosis, inhibits T-cell activation, suppresses B-cell differentiation, and regulates macrophage Fc receptors (13) . In patients who are refractory to these treatments, newer therapies including rituximab or the thrombopoetin receptor agonists should be considered.
Summary
We describe a rare case of patient with primary Sjögren's syndrome who developed very severe thrombocytopenia during the clinical course and successfully treated with high dose dexamethasone therapy.
